Health System Pilots See Lackluster Bundled Payment Results

Transparency in Coverage Data to Expose Ghost Rates and Hold Payers Accountable: David Muhlestein, PhD

Dexamethasone pretreatment significantly reduces GI complications in DLBCL patients undergoing R-CHOP, maintaining efficacy and improving safety.

January 20th 2026

Novel CLL Therapies Prompt New Treatment Considerations

David Muhlestein, PhD, breaks down ghost rates, data gaps, and why stronger oversight is needed to make Transparency in Coverage files usable for patients.

Listen

Ultimately, the authors said most patients will have more than one viable treatment option for first-line therapy, meaning that clinicians will need to rely on careful, informed discussions with patients. | Image credit: Eleni - stock.adobe.com

January 24th 2026

Managed Care Cast News Roundup: January 13, 2026

A review article focused on first-line treatment of chronic lymphocytic leukemia highlights the importance of shared decision-making.

January 13th 2026

Teclistamab Transforms Early Myeloma Care: Roberto Mina, MD

This week's news roundup covers updates in health policy, technology, and access to pharmaceuticals.

Listen

Roberto Mina, MD, Winship Cancer Institute of Emory University

CCCA Associated With Longer Time to Diagnosis Vs Other Scarring Alopecias

The results of the phase 3 MajesTEC-9 trial showcase teclistamab's efficacy for patients with relapsed/refractory multiple myeloma, explained Roberto Mina, MD.

The findings reinforce the need for earlier recognition of scarring alopecias—particularly CCCA—and improved education for clinicians. | Image Credit: cattyphoto - stock.adobe.com

Dexamethasone Before R-CHOP in DLBCL With GI Involvement Can Limit Complications, Retain Efficacy

Central centrifugal cicatricial alopecia (CCCA) faces significant diagnostic delays, highlighting the need for increased awareness and education among providers.

Related Content

January 25th 2026

Transparency in Coverage Data to Expose Ghost Rates and Hold Payers Accountable: David Muhlestein, PhD

Dexamethasone pretreatment significantly reduces GI complications in DLBCL patients undergoing R-CHOP, maintaining efficacy and improving safety.

January 20th 2026

Novel CLL Therapies Prompt New Treatment Considerations

David Muhlestein, PhD, breaks down ghost rates, data gaps, and why stronger oversight is needed to make Transparency in Coverage files usable for patients.

Listen

January 24th 2026

Managed Care Cast News Roundup: January 13, 2026

A review article focused on first-line treatment of chronic lymphocytic leukemia highlights the importance of shared decision-making.

January 13th 2026

Teclistamab Transforms Early Myeloma Care: Roberto Mina, MD

This week's news roundup covers updates in health policy, technology, and access to pharmaceuticals.

Listen

CCCA Associated With Longer Time to Diagnosis Vs Other Scarring Alopecias

The results of the phase 3 MajesTEC-9 trial showcase teclistamab's efficacy for patients with relapsed/refractory multiple myeloma, explained Roberto Mina, MD.